(Q44936222)

7 December 2017

title

Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients (English)

1 reference

7 December 2017

0 references

1 reference

parkinsonian syndrome

1 reference

Lior Greenbaum

1

1 reference

7 December 2017

Robert C Smith

2

1 reference

7 December 2017

Mordechai Lorberboym

3

1 reference

7 December 2017

Anna Alkelai

4

1 reference

7 December 2017

Polina Zozulinsky

5

1 reference

7 December 2017

Tzuri Lifschytz

6

1 reference

7 December 2017

Yoav Kohn

7

1 reference

7 December 2017

Ruth Djaldetti

8

1 reference

7 December 2017

Bernard Lerer

9

1 reference

7 December 2017

publication date

24 September 2011

1 reference

7 December 2017

number of pages

10

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

7 December 2017

volume

220

1 reference

7 December 2017

issue

3

1 reference

7 December 2017

page(s)

519-528

1 reference

Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Searching genetic risk factors for schizophrenia and bipolar disorder: learn from the past and back to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Pharmacogenomics in schizophrenia: the quest for individualized therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

The genome-wide structure of the Jewish people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

An instrumental study of the relationship between extrapyramidal signs and psychosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Coregulation of GATA factors by the Friend of GATA (FOG) family of multitype zinc finger proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Pharmacogenomic genome-wide association studies: lessons learned thus far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Neurological complications of psychiatric drugs: clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

21 January 2018

Neuroleptic intolerance

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Clinical characteristics of neuroleptic-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

FOG-2, a heart- and brain-enriched cofactor for GATA transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

PLINK: a tool set for whole-genome association and population-based linkage analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Drug-induced parkinsonism in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Spurious genetic associations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Genomewide association for schizophrenia in the CATIE study: results of stage 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Molecular cloning of FOG-2: a modulator of transcription factor GATA-4 in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

[123I]FP-CIT SPET imaging in drug-induced Parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Molecular imaging of the dopamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Atypical Antipsychotics and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2499-6

Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study

21 January 2018

1 reference

12 December 2020

Therapeutic implications of differential effects of new phenothiazine compounds

1 reference

12 December 2020

The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel.

1 reference

12 December 2020

Gonadal differentiation, sex determination and normal Sry expression in mice require direct interaction between transcription partners GATA4 and FOG2.

1 reference

12 December 2020

Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders.

1 reference

12 December 2020

Biperiden in the treatment of phenothiazine-induced extrapyramidal reactions

1 reference

12 December 2020

Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers

1 reference

12 December 2020

A survey of drug-induced extrapyramidal reactions

1 reference

12 December 2020

Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

10.1007/S00213-011-2499-6

Identifiers

DOI

1 reference

7 December 2017

1 reference